Repligen (RGEN) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Repligen Reports Fourth Quarter and Year 2015 Financial Results
February 25, 2016 7:30 AM EST- Constant currency revenue growth of 45% for the fourth quarter, 47% for the year -- Gross margin expansion of 420 basis points to 57.8% for the year -- Non-GAAP adjusted EPS of $0.40, an increase of 67% for the year -
WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the fourth quarter and year ended December 31, 2015. Below are the Company's performance highlights for these periods, followed by financial guidance for the year 2016 and access information for today's... More
